|
|
|
Inflarx N v (NASDAQ: IFRX) |
|
Inflarx N v
IFRX's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Inflarx N V growth rates, revenue grew
in IV. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Inflarx N V net loss increased from $-33 millions, to $-48 millions in IV. Quarter 2023,
• More on IFRX's Growth
|
|
Inflarx N V
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 3.32 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 855.28.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on IFRX's Valuation
|
|
|
|
|
Inflarx N V
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 3.32 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 855.28.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
Inflarx N V Price to Book Ratio is at 0.53 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01
• More on IFRX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
